Pancreatic Cancer Detection Consortium
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT06388967
- Status
- Recruiting
Conditions
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
- Pancreatic Cancer Non-resectable
- Pancreatic Cancer Resectable
- Pancreatic Cancer Stage
- Pancreatic Cancer Stage 0
- Pancreatic Cancer Stage I
- Pancreatic Cancer Stage II
- Pancreatic Cancer Stage III
- Pancreatic Cancer, Adult
- Pancreatic Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- PANcreatic cancer Exosome Early detectiON (PANXEON) — DIAGNOSTIC_TESTThis test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it
Study Details
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Key Dates
- Start date
- Mar 15, 2023
- Status verified
- Dec 2025
- Primary completion
- Jun 18, 2026
- Completion
- Jun 18, 2026
Study Design
- Enrollment
- 2,000 participants (estimated)
Arms
- Arm: Patients with Pancreatic Cancer Ductal Adenocarcinoma (Training)Individuals diagnosed with pancreatic ductal adenocarcinoma
- Arm: Individuals without Pancreatic Cancer Ductal Adenocarcinoma (Training)Individuals without pancreatic ductal adenocarcinoma
- Arm: Patients with Pancreatic Cancer Ductal Adenocarcinoma (Validation)Individuals diagnosed with pancreatic ductal adenocarcinoma
- Arm: Individuals without Pancreatic Cancer Ductal Adenocarcinoma (Validation)Individuals without pancreatic ductal adenocarcinoma
Primary Outcome Measure
Sensitivity [ Time Frame: Through study completion, an average of 1 year ]
Central Contacts
- Ajay Goel, PhD6262183452
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Translational Genomics Research Institute | Phoenix | Arizona | 85004 | Daniel Von Hoff Daniel Von Hoff (PRINCIPAL_INVESTIGATOR) Haiyong Han (SUB_INVESTIGATOR) Derek Cridebring (SUB_INVESTIGATOR) |
| Honorhealth | Scottsdale | Arizona | 85258 | Erkut Borazanci Erkut Borazanci (SUB_INVESTIGATOR) |
| City of Hope Medical Center | Monrovia | California | 91016 | Ajay Goel (PRINCIPAL_INVESTIGATOR) Stanley Hamilton (SUB_INVESTIGATOR) Vincent Chung (SUB_INVESTIGATOR) Caiming Xu (SUB_INVESTIGATOR) Alessandro Mannucci (SUB_INVESTIGATOR) |
| Hoag Center | Newport Beach | California | 92663 | Michael Demeure Michael Demeure (SUB_INVESTIGATOR) |
| OSF HealthCare | Peoria | Illinois | 61637 | Chandler Wilfong Chandler Wilfong (SUB_INVESTIGATOR) |
| Ochsner Medical Center | Jefferson | Louisiana | 70121 | John Bolton John Bolton (SUB_INVESTIGATOR) |
| Atlantic Health System | Morristown | New Jersey | 07960 | Angela Alistar Angela Alistar (SUB_INVESTIGATOR) Eric Whitman (SUB_INVESTIGATOR) |
| Piedmont Medical Center | Rock Hill | South Carolina | 29732 | Andrew Page Andrew Page (SUB_INVESTIGATOR) Eyal Meiri (SUB_INVESTIGATOR) |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Douglas Evans Douglas Evans (SUB_INVESTIGATOR) |
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the PancreasPHASE2 · Recruiting · Proton Collaborative Group · Jacksonville, Florida
- American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) RegistryRecruiting · University of Louisville · Birmingham, Alabama